WO2009103494A3 - Sgk1 als therapeutisches und diagnostisches target für karzinomatöse erkrankungen - Google Patents
Sgk1 als therapeutisches und diagnostisches target für karzinomatöse erkrankungen Download PDFInfo
- Publication number
- WO2009103494A3 WO2009103494A3 PCT/EP2009/001127 EP2009001127W WO2009103494A3 WO 2009103494 A3 WO2009103494 A3 WO 2009103494A3 EP 2009001127 W EP2009001127 W EP 2009001127W WO 2009103494 A3 WO2009103494 A3 WO 2009103494A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgk1
- therapeutic
- diagnostic target
- carcinomatous
- diseases
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Die vorliegende Erfindung betrifft Substanzen für die Therapie und Diagnose von Karzinomen unter Verwendung von sgk1 (serum and glucocorticoid dependent kinase 1) als therapeutisches bzw. diagnostisches Target.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008010363.2 | 2008-02-18 | ||
DE200810010363 DE102008010363A1 (de) | 2008-02-18 | 2008-02-18 | Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009103494A2 WO2009103494A2 (de) | 2009-08-27 |
WO2009103494A3 true WO2009103494A3 (de) | 2009-10-22 |
Family
ID=40445865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/001127 WO2009103494A2 (de) | 2008-02-18 | 2009-02-18 | Sgk1 als therapeutisches und diagnostisches target für karzinomatöse erkrankungen |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102008010363A1 (de) |
WO (1) | WO2009103494A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012158866A2 (en) | 2011-05-19 | 2012-11-22 | The Johns Hopkins University | Treatment of autoimmune disorders and infections using antagonists of sgk1 activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10149393A1 (de) * | 2001-09-28 | 2003-04-24 | Florian Lang | sgk1 als diagnostisches und therapeutisches target |
WO2005106491A2 (en) * | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
WO2006089230A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19708173A1 (de) | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
DE19917990A1 (de) | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
CN100529101C (zh) | 2003-03-03 | 2009-08-19 | 弗洛里安·朗 | 用作诊断和治疗靶的sgk1 |
WO2005094796A2 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for interfering with fibrosis |
TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
DE102006006648A1 (de) | 2006-02-14 | 2007-08-23 | Merck Patent Gmbh | Mandelsäurehydrazide |
-
2008
- 2008-02-18 DE DE200810010363 patent/DE102008010363A1/de not_active Withdrawn
-
2009
- 2009-02-18 WO PCT/EP2009/001127 patent/WO2009103494A2/de active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10149393A1 (de) * | 2001-09-28 | 2003-04-24 | Florian Lang | sgk1 als diagnostisches und therapeutisches target |
WO2005106491A2 (en) * | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
WO2006089230A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
Non-Patent Citations (5)
Title |
---|
JACOB TANGIR ET AL: "SGK1, a potential regulator of c-fms related breast cancer aggressiveness", CLINICAL & EXPERIMENTAL METASTASIS ; OFFICIAL JOURNAL OF THEMETASTASIS RESEARCH SOCIETY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 21, no. 6, 1 December 2004 (2004-12-01), pages 477 - 483, XP019235786, ISSN: 1573-7276 * |
MEYER T ET AL: "A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 43, no. 5, 15 May 1989 (1989-05-15), pages 851 - 856, XP002102539, ISSN: 0020-7136 * |
ROSARIO AMATO ET AL: "IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, vol. 85, no. 7, 15 June 2007 (2007-06-15), pages 707 - 721, XP019529803, ISSN: 1432-1440 * |
SHERK ANDREA B ET AL: "Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic", CANCER RESEARCH, vol. 68, no. 18, September 2008 (2008-09-01), pages 7475 - 7483, XP002520616, ISSN: 0008-5472 * |
SIMON PERIKLES ET AL: "Differential regulation of serum- and glucocorticoid-inducible kinase 1 (SGK1) splice variants based on alternative initiation of transcription", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, vol. 20, no. 6, 2007, pages 715 - 728, XP002520617, ISSN: 1015-8987 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009103494A2 (de) | 2009-08-27 |
DE102008010363A1 (de) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254663A1 (zh) | 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑 | |
WO2008100805A3 (en) | Anti-robo4 antibodies and uses therefor | |
WO2008153705A3 (en) | Methods of treating, diagnosing and detecting fgf21-associated disorders | |
WO2008097561A8 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
WO2011046964A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2013010136A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2010031825A3 (en) | Methods and compositions for the treatment of cancer | |
MX2010002312A (es) | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. | |
WO2008051805A3 (en) | Triazolo-pyridazine protein kinase modulators | |
WO2009007427A3 (en) | Novel antibodies inhibiting c-met dimerization, and uses thereof | |
IL188475A0 (en) | Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors | |
WO2008031551A3 (en) | Non-neuroendocrine cancer therapy | |
WO2006131591A3 (en) | An entacapone-containing oral dosage form | |
WO2006130399A3 (en) | Therapeutic combinations and methods including irm compounds | |
WO2007109236A3 (en) | Microrna fingerprints during human megakaryocytopoiesis | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2010057112A3 (en) | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets | |
WO2007109370A3 (en) | Methods for identifying polypeptide targets and uses thereof for treating immunological diseases | |
WO2008070344A3 (en) | Compositions and methods for binding sphingosine-1-phosphate | |
WO2010014784A3 (en) | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases | |
WO2010062377A3 (en) | Methods and compositions for the detection and treatment of preeclampsia | |
EP4279140A3 (de) | Humane antikorper gegen humanen gewebefaktor | |
WO2009036175A3 (en) | F1f0-atpase inhibitors and related methods | |
WO2007052023A3 (en) | Novel compounds | |
WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09713536 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09713536 Country of ref document: EP Kind code of ref document: A2 |